172@29@17@137!~!172@29@0@53!~!|news|tags|panacea-biotec.html!~!|controller|tag.php
panacea biotec
Jump to
84 Results Found
  • Panacea Biotec Consolidated March 2020 Net Sales at Rs 125.36 crore, up 4.82% Y-o-Y Jun 30, 2020 02:11 PM IST

    Panacea Biotec Consolidated March 2020 Net Sales at Rs 125.36 crore, up 4.82% Y-o-Y

  • Panacea Biotec bags orders worth $24 mn from UN agencies Dec 19, 2019 11:52 AM IST

    Panacea Biotec bags orders worth $24 mn from UN agencies

    "Panacea Biotec... has received awards worth USD 24.32 million from U N agencies (Unicef and PAHO) for supply of its Easyfive-TT, a fully liquid WHO prequalified wP-based Pentavalent vaccine (DTwPHepB-Hib)," the company said in a filing to BSE.

  • Panacea Biotec share price jumps 11% on $24 million order Dec 19, 2019 11:24 AM IST

    Panacea Biotec share price jumps 11% on $24 million order

    "UNICEF award is for calendar year 2020 and award of PAHO is for three calendar years i.e. 2020-2022," company said in its BSE filing.

  • Panacea Biotec launches generic diabetes treatment drug in India Dec 10, 2019 01:55 PM IST

    Panacea Biotec launches generic diabetes treatment drug in India

    The four formulations are Vildagliptin 50 mg, Vildagliptin 50 mg + Metformin HCL 500 mg, Vildagliptin 50 mg + Metformin HCL 850 mg and Vildagliptin 50 mg + Metformin HCL 1,000 mg, Panacea Biotec said in a filing to the BSE.

  • Panacea Biotec rallies 14% on Rs 992 crore investment from IndiaRF Apr 09, 2019 09:29 AM IST

    Panacea Biotec rallies 14% on Rs 992 crore investment from IndiaRF

    At 0924 hrs, Panacea Biotec was quoting Rs 207.55, up 14.57 percent on the BSE.

  • Bain, Piramal-led fund offers Panacea a Rs 992cr bail-out deal Apr 08, 2019 08:32 PM IST

    Bain, Piramal-led fund offers Panacea a Rs 992cr bail-out deal

    The joint venture fund has been active in the pharma business and the announcement comes after the February 26 announcement by Panacea about reaching a one-time settlement with the lenders to pay off Rs 864 crore of debt.

  • Panacea Biotec Standalone December 2018 Net Sales at Rs 113.85 crore, down 25.18% Y-o-Y Feb 18, 2019 11:11 AM IST

    Panacea Biotec Standalone December 2018 Net Sales at Rs 113.85 crore, down 25.18% Y-o-Y

  • Panacea inks pact with Natco, Breckenridge for cancer drug Aug 27, 2018 05:12 PM IST

    Panacea inks pact with Natco, Breckenridge for cancer drug

    Panacea will be responsible for manufacture and supply of the product, which will be marketed, sold and distributed by Breckenridge in the US.

  • Panacea Biotec stock jumps 6% on settlement agreement with Celgene for Abraxane generic Jun 18, 2018 12:50 PM IST

    Panacea Biotec stock jumps 6% on settlement agreement with Celgene for Abraxane generic

    As part of the settlement agreement, Panacea and Apotex will receive a non-exclusive license under which Panacea Biotec may begin selling generic version of Abraxane in the US.

  • Panacea Biotec clears US FDA inspection for Baddi formulation facility Mar 09, 2018 04:17 PM IST

    Panacea Biotec clears US FDA inspection for Baddi formulation facility

    The company's Baddi facility manufactures anti-cancer injectables and oral solid dosage formulations.

  • Panacea Biotec gets USFDA nod to file for generic cancer drug Nov 30, 2017 01:24 PM IST

    Panacea Biotec gets USFDA nod to file for generic cancer drug

    The company's abbreviated new drug application (ANDA) for Paclitaxel Protein bound particles for injectable suspension, 100mg/vial has been accepted for filing by the US Food and Drug Administration (USFDA), Panacea Biotec said in a BSE filing.

  • Panacea Biotec gets USFDA nod to launch Prasugrel tablets Oct 24, 2017 02:45 PM IST

    Panacea Biotec gets USFDA nod to launch Prasugrel tablets

    The company is also entitled for 180 days of shared market exclusivity for the Prasugrel HCL tablets, it added.

  • Panacea shares rise 14% on generic drug launch in US Oct 24, 2017 01:46 PM IST

    Panacea shares rise 14% on generic drug launch in US

    Panacea's Prasugrel copies are first-to-file abbreviated new drug applications (ANDAs) approved by US FDA - making eligible for 180-days of shared marketing exclusivity under the provisions of Hatch-Waxman Act.

  • Panacea Biotec expands collaboration with US firm for Prasugrel launch; stock up 16% Sep 11, 2017 12:32 PM IST

    Panacea Biotec expands collaboration with US firm for Prasugrel launch; stock up 16%

    Prasugrel is currently having annual sales of approximately USD 600 million in USA.

  • Panacea promoters may demerge real estate biz into separate co Aug 30, 2017 03:38 PM IST

    Panacea promoters may demerge real estate biz into separate co

    Under a memorandum of acknowledgement of oral family settlement, the promoters have decided that the company's real estate arm, Radhika Heights Ltd, would be managed by Ravinder Jain and may become a separate listed entity, Panacea Biotec said in a filing to the BSE.

  • Don't expect unusual risks in development of drugs: Panacea Biotech Aug 01, 2017 02:09 PM IST

    Don't expect unusual risks in development of drugs: Panacea Biotech

    Panacea Biotec has entered into a joint collaboration with Bion Pharma. In an interview to CNBC-TV18, Rajesh Jain, Joint MD of Panacea Biotech spoke about the latest happenings in his company and sector.

  • Panacea Biotec zooms 10% on collaboration with US firm for 7 complex generics Jul 28, 2017 11:25 AM IST

    Panacea Biotec zooms 10% on collaboration with US firm for 7 complex generics

    The seven abbreviated new drug applications are currently under development at Panacea Biotec, representing a total estimated market potential of more than USD 800 million.

  • Narayana Hrudayalaya to buy NewRise Healthcare Apr 21, 2017 01:41 PM IST

    Narayana Hrudayalaya to buy NewRise Healthcare

    The acquisition will help expand its footprint in Gurugram in northern India, Narayana Hrudayalaya said on Friday.

  • Panacea Biotec up 9%, to sell 100% stake in arm to Narayana Hrudayalaya Apr 21, 2017 01:27 PM IST

    Panacea Biotec up 9%, to sell 100% stake in arm to Narayana Hrudayalaya

    The company has entered into definitive agreement to divest its 100 percent stake held in NewRise Healthcare to Narayana Hrudayalaya.

  • Panacea Biotec launches vaccine for newborns Mar 29, 2017 06:00 PM IST

    Panacea Biotec launches vaccine for newborns

    Drug firm Panacea Biotec today announced launch of EasySix, a liquid hexavalent combination vaccine indicated for immunisation of newborn babies against common preventable diseases.

  • Stocks in news: Tata Motors, DLF, Cadila, JSPL, MOIL, Intellect Feb 15, 2017 08:00 AM IST

    Stocks in news: Tata Motors, DLF, Cadila, JSPL, MOIL, Intellect

    Tata Motors | Sun Pharma | DLF | Cadila Health | Jindal Steel | SpiceJet | Adani Enterprises | MOIL | Cox & Kings | HDIL | Liberty Shoes | Voltas | National Fertilisers | Ashiana Housing | Power Mech | Intellect Design Arena are stocks, which are in the news today.

  • FDA nod for anti-migraine drug to lift US revenues: Panacea Jan 19, 2017 02:03 PM IST

    FDA nod for anti-migraine drug to lift US revenues: Panacea

    The company Wednesday received the US Food and Drug Administration (USFDA) approval for an anti-migraine drug for which it had filed the Abbreviated New Drug Application (ANDA) in 2012.

  • Panacea inks pact with UNICEF,gets USFDA nod for migraine drug Jan 18, 2017 01:40 PM IST

    Panacea inks pact with UNICEF,gets USFDA nod for migraine drug

    The company has also received a notification from Pan American Health Organisation (PAHO) for purchase of Easyfive-TT vaccine in the event the agency should have any requirements through December, 31, 2019.

  • Top buzzing midcap stocks to trade on January 18 Jan 18, 2017 01:04 PM IST

    Top buzzing midcap stocks to trade on January 18

    Here are a few top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today -- Delta Corp, Panacea Bio, Vedanta, United Spirits, Cholamandalam Finance, Escorts, GSPL, Kaveri Seeds and Havells India.

  • Buy NTPC, Tata Steel, Power Grid: Sudarshan Sukhani Jan 18, 2017 10:52 AM IST

    Buy NTPC, Tata Steel, Power Grid: Sudarshan Sukhani

    Sudarshan Sukhani of s2analytics.com is of the view that NTPC, Tata Steel and Power Grid are excellent buying opportunities.

Sections